Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2010-11-26 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
关于挂牌转让持有北京嘉事大恒制药有限公司100％股权、北京大恒倍生制药厂有限公司75%股权的后续进展公告（一）
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a transaction involving the transfer of equity interests in two pharmaceutical companies held by 嘉事堂药业股份有限公司. It includes details about the transaction process, audit and valuation reports, financial data of the target companies, and references to board resolutions and independent opinions. The document does not contain a full annual or interim financial report but rather provides updates and supporting information related to a capital transaction. It is not a full audit report, earnings release, or management discussion. The content fits best with a Capital/Financing Update (CAP) as it concerns the progress and details of a share transfer transaction and related financial evaluations.
2010-11-26 Chinese
关于召开2010年第二次临时股东大会的公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is an announcement regarding the convening of the 2010 second extraordinary general meeting of shareholders for 嘉事堂药业股份有限公司. It details the meeting's basic information, agenda items to be discussed, registration procedures, contact information, and related attachments such as board resolutions, independent opinions, amended articles of association, and audit reports. The document does not contain actual financial statements or detailed financial analysis but serves to inform shareholders about the meeting and its agenda. The length is about 2,423 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of a Proxy Solicitation & Information Statement (PSI), as it provides information to shareholders to prepare for voting at the meeting.
2010-11-26 Chinese
北京大恒倍生制药厂有限公司审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an audit report (审计报告) for Beijing Daheng Beisheng Pharmaceutical Factory Co., Ltd. It includes an auditor's opinion, responsibilities of management and auditors, and detailed financial statements such as the balance sheet, income statement, cash flow statement, and statement of changes in equity for the period ending October 31, 2010. The content is comprehensive and contains actual financial data and analysis, not just an announcement or certification. The presence of detailed financial statements and audit opinion indicates this is a standalone audit report rather than a full annual report or other filing type. Q3 2010
2010-11-26 Chinese
北京嘉事大恒制药有限公司股权转让项目股东全部权益价值资产评估报告书
Audit Report / Information Classification · 95% confidence The document is a detailed asset valuation report for Beijing Jiashidaheng Pharmaceutical Co., Ltd., prepared by Beijing Tiankun United Asset Appraisal Co., Ltd. It includes extensive financial data, asset and liability details, valuation methods, legal and regulatory references, and a comprehensive explanation of the valuation process. The report is dated November 25, 2010, with a valuation base date of October 31, 2010. The content is focused on the market value assessment of the company's entire shareholder equity for a planned equity transfer. This is a standalone asset valuation report, not an annual or interim financial report, nor an announcement or certification. It is not a regulatory filing or a brief announcement but a full detailed valuation report. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit or valuation reports and applied accounting principles, excluding full annual reports. 9M 2010
2010-11-26 Chinese
北京大恒倍生制药厂有限公司股权转让项目股东全部权益价值资产评估报告书
Audit Report / Information Classification · 95% confidence The document is a detailed asset valuation report prepared by an asset evaluation company for a pharmaceutical company regarding the shareholder equity value for a share transfer project. It includes extensive financial data, asset and liability details, valuation methods, legal and regulatory references, and audit confirmations. The document is titled as an "资产评估报告书" (Asset Evaluation Report) and contains substantive financial data and analysis related to the valuation of shareholder equity as of a specific date (October 31, 2010). It is not an announcement or a brief summary but a full report with detailed financial and valuation content. This fits the definition of an Audit Report / Information (AR) as it is a standalone valuation report with applied accounting principles and detailed financial analysis, but it is not a full Annual Report (10-K) or an Interim Report (IR). Therefore, the appropriate classification is AR with high confidence. Q4 2010
2010-11-26 Chinese
北京嘉事大恒制药有限公司审计报告
Audit Report / Information Classification · 100% confidence The document is an audit report for Beijing Jiashi Daheng Pharmaceutical Co., Ltd. It includes an auditor's opinion, detailed financial statements such as the balance sheet, income statement, cash flow statement, and statement of changes in equity for the period ending October 31, 2010. The presence of the auditor's opinion, the detailed financial statements, and the explicit mention of auditing standards and responsibilities indicate this is a standalone audit report. It is not a full annual report (10-K) because it focuses on the audit opinion and financial statements without broader management discussion or other annual report components. The document length (15,000 characters) and content confirm it is not a brief announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR). 9M 2010
2010-11-26 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.